Study of Prevalence of Eating Disorder in Liver Transplant Patients

Completed

• Conditions: Liver Transplant; Complications; Alcohol Use Disorder; Cirrhosis Alcoholic; Eating Disorders; Eating Disorder Binge

• Registration Number: NCT06093919
• Lead Sponsor: Centre Hospitalier Henri Laborit

Brief Summary

The main goal of this observational study is to measure the prevalence of binge eating disorder in liver transplant patients by evaluating the responses to the Bulimia Test.

Secondary objectives of the study are to:

* Determine the prevalence of binge eating disorders in liver transplant patients following alcoholic cirrhosis, evaluated by the Bulimia Test;

* Study the association between the presence of eating disorder behaviours and liver damage : hepatic steatosis and fibrosis determined by Fibroscan (Transient elastography and controlled attenuation parameter)

* Study the association between presence of eating disorder behaviours and alcohol use disorder, measured by Alcohol Use Disorders Identification Test-Consumption

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-10-17
• Study First Submitted QC: 2023-10-17
• Study First Posted: 2023-10-23
• Study Start: 2024-02-12
• Primary Completion: 2024-06-30
• Status Verified: 2024-08
• Study Completion: 2024-08-14
• Last Update Submitted: 2024-08-19
• Last Update Posted: 2024-08-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 118

Inclusion Criteria

• over 18 years old
• had a liver transplant and followed at University Hospital of Poitiers
• responded to the Bulimia Test-Revised and to the Alcohol Use Disorders Identification Test-Consumption
• had a Fibroscan within the year

Exclusion Criteria

• Patient without Fibroscan and not responded to both scale : Bulimia Test-Revised and Alcohol Use Disorders Identification Test-Consumption

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of binge eating disorder in liver transplant patients	1 year	The prevalence is defined as the percentage of liver transplant patients with a score higher than 88 on the Bulimia Test-Revised. The Bulimia Test-Revised is a validated test. It is a 36 item self-report questionnaire to assess the presence of bulimic symptoms. Scores range from 29-140 with those greater than 104 being indicative of bulimia nervosa.

Secondary Outcome Measures

Name	Time	Method
Correlation between the BulimiaTest-Revised score and liver damage determined by the Fibroscan	1 year	The Correlation was defined by the coefficient between the bulimia-Test score and the liver damage defined by the levels of hepatic steatosis and fibrosis witch are measured by Transient elastography and controlled attenuation parameter using Fibroscan. The Bulimia Test-Revised is a validated, it is a 36 item self-report questionnaire to assess the presence of bulimic symptoms. Scores range from 29-140 with those greater than 104 being indicative of bulimia nervosa.
Prevalence for binge eating disorder in liver transplant patients following alcoholic cirrhosis	1 year	The prevalence was defined as the percentage of liver transplant patients following alcoholic cirrhosis with a score higher than 88 on the Bulimia Test-Revised. The Bulimia Test-Revised is a validated test. It is a 36 item self-report questionnaire to assess the presence of bulimic symptoms. Scores range from 29-140 with those greater than 104 being indicative of bulimia nervosa.
Correlation between the Bulimia-Test score and the Alcohol Use Disorders Identification Test-Consumption score	1 year	The Correlation was defined by the coefficient between the bulimia-Test score and the Alcohol Use Disorders Identification Test-Consumption score. The Bulimia Test-Revised is a validated. It is a 36 item self-report questionnaire to assess the presence of bulimic symptoms. Scores range from 29-140 with those greater than 104 being indicative of bulimia nervosa.; The Alcohol Use Disorders Identification Test-Consumption score is a validated test. It's scored on a scale of 0-12 (scores of 0 reflect no alcohol use). For men, a score of 4 or more is considered positive; for women, a score of 3 or more is considered positive. Generally, the higher the AUDIT-C score, the more likely the patient's drinking is affecting his/her health and safety.

Trial Locations

Locations (2)

Centre Hospitalier Henri Laborit; 🇫🇷 Poitiers, France

University Hospital of Poitiers (CHU de Poitiers); 🇫🇷 Poitiers, France